What is the 13F Pro Quality Score for CRON?

13F Pro ranks Cronos Group Inc. (CRON) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRON's current score at https://13fpro.ai/research/CRON (free sign-up required for the full ranking).

Which hedge funds own the most CRON stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CRON include Chescapmanager, D. E. Shaw & Co.,, Pillsbury Lake Capital. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CRON as soon as new 13F filings post.

Where does 13F Pro source CRON data?

All Cronos Group Inc. fundamentals and ownership data come directly from SEC EDGAR. Cronos Group Inc. files with the SEC under CIK 1656472. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRON in?

Cronos Group Inc. (CRON) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRON research updated on 13F Pro?

CRON's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cronos Group Inc.(CRON)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1656472 CRON stock profile & AI dashboard →

13F Pro Quality Score

48.6/100

Rank #1,549 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

86.9/100

Profitability

65.5/100

Balance Sheet

39.2/100

Earnings Quality

30.0/100

Free Cash Flow

32.8/100

Institutional Flow

27.1/100

Revenue Scale

21.0/100

Dilution Risk

26.5/100

CRON Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cronos Group Inc. (CRON), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRON at 48.6/100 on a 32-signal composite quality model, placing it at rank #1,549 of 2,879 stocks — the bottom half of the AI-ranked universe. CRON scores in the top quartile across revenue growth (86.9). Areas of concern include revenue scale (21.0) and institutional flow (27.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Cronos Group Inc. reports quarterly revenue of $45.2M, net income of $13.8M, free cash flow of $9.0M. Top institutional holders of CRON by reported 13-F value include Chescapmanager, D. E. Shaw & Co.,, Pillsbury Lake Capital, based on the most recent SEC filings. CRON trades on the Nasdaq exchange and files with the SEC under CIK 1656472. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cronos Group Inc. directly from SEC EDGAR. Cronos Group Inc.'s 13F Pro composite quality score has ranged between 8 and 68 since 2021, currently 48.6 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Cronos Group Inc.

Quirks, history, and lore behind CRON — the kind of stuff that makes a stock memorable.

1
The Basics
A Canadian company in the healthcare sector · listed on Nasdaq · operating in a heavily regulated, plant-based consumer industry.
2
The Numbers
A small-cap with revenue in the tens of millions annually — big ambitions, modest returns, and a balance sheet kept alive partly by a major strategic investment from a global beverage giant.
3
The History
Founded in 2012 in Canada, it rode the wave of cannabis legalization to become one of the first pot companies to list on a major U.S. exchange.
4
The Secret
Altria Group — the tobacco conglomerate behind Marlboro — took a large equity stake in the company, betting that nicotine customers and cannabis customers might overlap nicely.
5
The Lore
Its name evokes the Greek god of time, which feels fitting for a company that has spent years waiting for U.S. federal cannabis reform that keeps not quite arriving.
6
The Giveaway
Its ticker symbol is literally a crow's call — CRON — and this Canadian cannabis producer has been growing, processing, and selling legal marijuana since before it was cool.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$45.2M

Net Income

Q1 2026

$13.8M

Free Cash Flow

Q1 2026

$9.0M

ROIC

Q1 2026

-0.2%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+34.8% YoY

$117.6MFY 2024

FY21 $64.6MFY22 $86.7MFY23 $87.2MFY24 $117.6M

Net Income

+155.5% YoY

$41.1MFY 2024

FY21 $-396.1MFY22 $-168.7MFY23 $-74.0MFY24 $41.1M

Operating Income

+9.8% YoY

$-76.5MFY 2024

FY21 $-292.0MFY22 $-111.4MFY23 $-84.8MFY24 $-76.5M

EPS (Diluted)

+157.9% YoY

$0.11FY 2024

FY21 $-1.07FY22 $-0.45FY23 $-0.19FY24 $0.11

Total Assets

+2.3% YoY

$1.17BFY 2024

FY21 $1.40BFY22 $1.21BFY23 $1.14BFY24 $1.17B

Op. Cash Flow

+144.0% YoY

$18.8MFY 2024

FY21 $-153.6MFY22 $-88.9MFY23 $-42.8MFY24 $18.8M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$117.6M +34.8%	$87.2M +0.6%	$86.7M +34.4%	$64.6M +171.8%	$23.8M
Net Income	$41.1M +155.5%	$-74.0M +56.2%	$-168.7M +57.4%	$-396.1M -134.0%	$1.17B
Operating Income	$-76.5M +9.8%	$-84.8M +23.9%	$-111.4M +61.8%	$-292.0M -90.4%	$-153.3M
EPS (Diluted)	$0.11 +157.9%	$-0.19 +57.8%	$-0.45 +57.9%	$-1.07 -132.1%	$3.33
Total Assets	$1.17B +2.3%	$1.14B -6.0%	$1.21B -13.2%	$1.40B -33.1%	$2.09B
Operating Cash Flow	$18.8M +144.0%	$-42.8M +51.8%	$-88.9M +42.1%	$-153.6M -17.1%	$-131.2M

AI Insight: CRON Financial Trends

Revenue stabilized at $45M while operating losses narrowed, but profitability remains volatile and dependent on non-operating items.

• Revenue grew from $28M in Q2 2024 to $45M in Q1 2026, a 61% increase over 9 quarters.

• Operating income improved from -$34M in Q3 2024 to -$2M in Q1 2026, showing consistent operational tightening.

• Operating cash flow remained consistently positive ($2M–$13M range) despite operating losses, suggesting non-cash charges dominate.

⚠ Net income highly volatile: swung from -$40M in Q2 2025 to +$26M in Q3 2025 to -$2M in Q4 2025 to +$14M in Q1 2026.

⚠ Operating margin still negative at -4% in Q1 2026; no quarter in dataset shows positive operating profit.

AI Insight: CRON Ratio Trends

Operating margin structural improvement toward breakeven masks persistent negative ROIC and erratic profitability across quarters.

• Operating margin improved from -56.0% in Q2 2024 to -4.0% in Q1 2026, signaling cost discipline; TTM OpMargin at -9.5%.

• Net profitability remains highly volatile: Q4 2024 hit 144.3% NPM, Q2 2025 dropped -118.7%, Q1 2026 recovered to 30.4%.

• ROIC consistently negative across all periods (range -12.4% to -0.2%), with TTM ROIC at -1.4%, indicating value destruction.

⚠ ROE/ROA swung from +16.4%/+15.0% in Q4 2024 to -14.7%/-13.5% in Q2 2025; Q1 2026 recovery to +5.1%/+4.7% requires sustained confirmation.

⚠ Negative ROIC persistence despite OpMargin gains suggests balance-sheet or working-capital drag; monitor cash conversion.

Get alerted when CRON's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cronos Group Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRON

Chescapmanager LLC
$19.9M7,942,737 sh
D. E. Shaw & Co., Inc.
$19.1M7,618,227 sh
Pillsbury Lake Capital LLC
$10.6M4,223,004 sh
Toroso Investments, LLC
$10.1M4,026,892 sh
DIMENSIONAL FUND ADVISORS LP
$6.7M2,679,051 sh
RENAISSANCE TECHNOLOGIES LLC
$5.0M2,009,549 sh
PRELUDE CAPITAL MANAGEMENT, LLC
$3.8M1,500,000 sh
CIBC WORLD MARKET INC.
$3.4M1,346,820 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$3.2M1,260,467 sh
GROUP ONE TRADING, L.P.
$2.7M1,057,600 sh

Fund	Value	Shares
Chescapmanager LLC	$19.9M	7,942,737
D. E. Shaw & Co., Inc.	$19.1M	7,618,227
Pillsbury Lake Capital LLC	$10.6M	4,223,004
Toroso Investments, LLC	$10.1M	4,026,892
DIMENSIONAL FUND ADVISORS LP	$6.7M	2,679,051
RENAISSANCE TECHNOLOGIES LLC	$5.0M	2,009,549
PRELUDE CAPITAL MANAGEMENT, LLC	$3.8M	1,500,000
CIBC WORLD MARKET INC.	$3.4M	1,346,820
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$3.2M	1,260,467
GROUP ONE TRADING, L.P.	$2.7M	1,057,600

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRON on your watchlist

Track score changes the day Cronos Group Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRON a good stock to buy?

13F Pro's AI-powered analysis of Cronos Group Inc. (CRON) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRON are available on the CRON stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CRON?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRON. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cronos Group Inc.'s investment landscape.